The market expects Tarsus Pharmaceuticals, Inc. (TARS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the ...

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call ...

IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ Chief Medical Advisor ...

Core Insights - Tarsus Pharmaceuticals, Inc. (TARS) shares experienced a significant increase of 10.6% to $43.87, with a notable trading volume, reflecting a 20.6% gain over the past four weeks [1][2] Company Performance - The rise in stock price is linked to positive investor sentiment regarding Tarsus' marketed product, Xdemvy, which is approved for treating demodex blepharitis, and the potential expansion of its label to include meibomian gland disease [2] - Tarsus has a clinical pipeline with promising candidates such as TP-04 for papulopustular rosacea and TP-05 for Lyme disease prevention [2] Financial Expectations - The company is projected to report a quarterly loss of $0.90 per share, reflecting a year-over-year increase of 29.7%, while revenues are expected to reach $42.18 million, a substantial increase of 2155.6% from the previous year [3] - The consensus EPS estimate has been revised 1.3% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not correlate with price appreciation [4] Industry Context - Tarsus Pharmaceuticals operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Seer, Inc. (SEER), closed 2.1% higher at $1.98, but has seen a -1.5% return over the past month [4]

Core Insights - Tarsus Pharmaceuticals has launched a direct-to-consumer TV campaign for XDEMVY, the first FDA-approved treatment for Demodex blepharitis, which affects approximately 25 million people in the U.S. [1][4][7] Group 1: Campaign Overview - The campaign titled "Your Mitey Problem" creatively illustrates the impact of Demodex mites on patients' eyelids, showcasing a 'party' of mites causing irritation and inflammation [3][4] - The campaign aims to educate patients about Demodex blepharitis and encourage them to consult eye care providers regarding XDEMVY [4][5] - The multi-channel campaign is currently live on connected TV devices, streaming channels, and includes digital and social media components [5] Group 2: Product Information - XDEMVY (lotilaner ophthalmic solution) 0.25% is designed to target and eradicate Demodex mites, addressing the root cause of Demodex blepharitis [8] - The active ingredient, lotilaner, selectively inhibits GABA-Cl channels, effectively eradicating the mites [8] - Clinical trials involving over 800 patients demonstrated that XDEMVY met primary and secondary endpoints with no serious treatment-related adverse events [8][10] Group 3: Company Background - Tarsus Pharmaceuticals focuses on unmet medical needs, particularly in eye care, and is advancing a pipeline that includes treatments for various diseases [9] - The company is also investigating additional products for conditions such as Meibomian Gland Disease and Rosacea, all currently in Phase 2 trials [9]

Group 1 - The company has a strong academic foundation with expertise in finance and medicine, enhancing its capabilities in the financial sector [1] - The firm specializes in income investing and biotech/pharma investing, leveraging nearly a decade of experience [2][3] - The organization focuses on identifying both short-term catalyst-driven opportunities and long-term investment strategies in the biotech sector [3] Group 2 - Subscribers receive regular portfolio trade alerts and have access to an interactive chat feature, promoting engagement and support [4] - The company has published a best-selling book on biotech investing and offers educational courses, further establishing its authority in the field [4] - The firm provides custom biotech analysis upon request, catering to specific investor needs [5]

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in ...

Tarsus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call August 8, 2024 Today's Speakers Bobak Azamian, M.D., Ph.D. Chief Executive Officer and Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial Officer and Chief Strategy Officer 2 2 © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.20%. A quarter ago, it was expected that this company would post a loss of $1.15 per share when it actually produced a loss of $1.01, delivering a surprise of 12.17%. Over the last four quarters, the compa ...

About Tarsus Pharmaceuticals, Inc. Media Contact: Adrienne Kemp Sr. Director, Corporate Communications (949) 922-0801 akemp@tarsusrx.com IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second q ...